Flexible Sigmoidoscopy Screening Reduces Mortality

Share this content:
Flexible Sigmoidoscopy Screening Reduces Mortality
Flexible Sigmoidoscopy Screening Reduces Mortality

MONDAY, Aug. 21, 2017 (HealthDay News) -- Screening with flexible sigmoidoscopy reduces all-cause mortality, according to a research letter published online Aug. 22 in the Annals of Internal Medicine.

Andrew W. Swartz, M.D., from the Yukon-Kuskokwim Delta Regional Hospital in Bethel, Alaska, and colleagues examined the results of the Norwegian Colorectal Cancer Prevention (NORCCAP) study for a Simpson paradox and repeat meta-analysis of all-cause mortality outcomes for screening flexible sigmoidoscopy. Data were extracted from four studies, and meta-analysis was performed.

The researchers found that the relative risk for all-cause mortality favoring screening was 0.96 (95 percent confidence interval [CI], 0.87 to 1.06) in the younger cohort (age 50 to 54 years) of the NORCCAP study, while the relative risk for the older cohort (ages 55 to 64 years) was 0.98 (95 percent CI, 0.94 to 1.03). The relative risk for the combined summary estimate of these cohorts was 0.98 (95 percent CI, 0.94 to 1.02). When the cohorts were aggregated into a single group, the relative risk was 1.07 (95 percent CI, 1.02 to 1.12), favoring no screening. Using the individual NORCCAP study cohorts, flexible sigmoidoscopy reduced all-cause mortality (relative risk, 0.975; 95 percent CI, 0.959 to 0.992; P = 0.004) at 11 to 12 years. The absolute risk reduction was 3.0 deaths per 1,000 persons invited to screening after 11.5 years of follow-up.

"We believe that colorectal cancer screening guidelines warrant reassessment to incorporate this evidence," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »